Fenwick has submitted a comment letter responding to the SEC's request for comments regarding potential amendments to modernize and simplify disclosure requirements of Regulation S-K. The comment letter addresses opportunities to eliminate redundancy, reduce compliance costs, and improve the quality of disclosures for technology and life sciences companies.
The letter emphasizes:
- The importance of eliminating redundancy and pruning away disclosures that are not meaningful to investors, which will lead to better and more comprehensible disclosures at lower cost for both investors and issuers
- The SEC should consider amendments to existing related party transaction requirements under Item 404; executive compensation disclosure requirements under Item 402, Item 5.02, and Item 5.07 of Form 8-K; and periodic reporting requirements, such as the human capital disclosure under Item 101, summary risk factors under Item 105, market price of and dividends on the registrant’s common equity and related stockholder matters under Item 201, and quantitative and qualitative disclosures about market risk under Item 305.
- The value of less prescriptive and more principles-based disclosure requirements as an effective mechanism to solicit information that is meaningful to investors but tailored to the realities of technology and life sciences companies
- The need to reaffirm materiality as the governing threshold for all disclosure obligations, ensuring that requirements are calibrated strictly to what a reasonable investor would consider important
- Support for expanded scaled disclosure for smaller reporting companies and emerging growth companies to reduce disproportionate compliance burdens and encourage more companies to enter and remain in the public markets
Read the letter